NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Statin Therapy for Ischemic and Nonischemic Cardiomyopathy

CompletedPhase 4

Sponsor: Philip Binkley

Conditions: Cardiovascular Disease, Cardiomyopathy, Heart Disease, Myocardial Disease, Myocardial Ischemia

Interventions: Atorvastatin Calcium

Countries: United States

The purpose of this study is to see if taking a cholesterol lowering drug Lipitor (Atorvastatin Calcium)will increase the number of endothelial progenitor cells (EPC's) circulating in the blood of heart failure patients taking this cholesterol-lowering drug, and if this will also show an improvement in the damaged areas of the patient's hearts as documented by MRI scans.

Eligibility overview

Sex: ALL

Age: 18 Years to 85 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Ischemic Cardiomyopathy (as defined above) with ejection fraction \< 35%
* Non-ischemic Cardiomyopathy with ejection fraction \< 35%
* NCEP ATPIII indication for therapy with a statin drug
* No statin therapy within previous 6 months of study enrollment
* Prescribed stable doses of standard heart failure therapies including beta blocking agents, angiotensin converting enzyme inhibitors or angiotensin receptor blockers, and diuretic agents as required

Exclusion Criteria:

* Pregnant or lactating
* Myocardial infarction within 6 months preceding study enrollment
* Primary valvular heart disease
* Surgical or catheter based revascularization within the preceding 6 months
* Documented viral or inflammatory myocarditis or cardiomyopathy
* Peripartum cardiomyopathy
* Infiltrative cardiomyopathies
* Chemotherapy associated cardiomyopathy
* Without indication for statin therapy
* Contraindication to statin therapy including hepatic dysfunction, history of rhabdomyolysis or prior intolerance of statin therapy
* Contraindication to magnetic resonance imaging

Locations (1)

Columbus, Ohio, United States